▶ KISSPEPTIN-10 · SUBTOPIC · DOSING LITERATURE

KISSPEPTIN-10 Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of KISSPEPTIN-10. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for KISSPEPTIN-10 reports the following route(s) of administration: Subcutaneous (research), Intravenous (clinical research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of KISSPEPTIN-10.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for KISSPEPTIN-10 of approximately Very short (minutes) plasma. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of KISSPEPTIN-10. Refer to the original publication for full protocol detail.

Dhillo WS, Chaudhri OB, Patterson M, et al. (2005) reports the KISSPEPTIN-10 protocol used in Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males, published in J Clin Endocrinol Metab. PMID 15883247. See the source for the protocol-level dose range, frequency, and duration. link
de Roux N, et al. (2003) reports the KISSPEPTIN-10 protocol used in Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54, published in Proc Natl Acad Sci U S A. PMID 12944565. See the source for the protocol-level dose range, frequency, and duration. link
Abbara A, Jayasena CN, Christopoulos G, et al. (2015) reports the KISSPEPTIN-10 protocol used in Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization, published in J Clin Invest. See the source for the protocol-level dose range, frequency, and duration. link

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 14-21 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only in the United States.

WADA · Not specifically named on the WADA Prohibited List as of 2026. GnRH-axis-active compounds (e.g., hCG) are prohibited for male athletes under S2; kisspeptin may fall under regulator discretion.

◀ KISSPEPTIN-10 OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19